

BIOLIDICS LIMITED
(Company Registration Number: 200913076M)

INCORPORATION OF WHOLLY-OWNED SUBSIDIARY IN AUSTRALIA

The board of directors (“**Board**” or “**Directors**”) of Biolidics Limited (the “**Company**” and, together with its subsidiary, the “**Group**”) wishes to announce that the Company has incorporated a wholly-owned subsidiary in Australia. The details of the subsidiary is as follows:-

Name of subsidiary: Biolidics Pty Ltd

Issued and paid-up share capital: AU\$1,500,000

Principal activity: Technology development, technology transfer, marketing and sale of biomedical technology related products and services

The incorporation of the subsidiary was funded through internal resources and is not expected to have any material impact on the net tangible assets and earnings per share of the Group for the financial year ending 31 December 2019.

None of the Directors or substantial shareholders of the Company and their respective associates has any interest, direct or indirect, in the incorporation of the subsidiary, save for their shareholdings in the Company, if any.

BY ORDER OF THE BOARD

Lew Kwang Ping
Executive Director and Chief Executive Officer
17 September 2019

IMPORTANT NOTICE

This announcement has been prepared by Biolidics Limited (the “Company”) and has been reviewed by the Company’s sponsor, United Overseas Bank Limited (the “Sponsor”), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.